Press Releases

Press Releases
Date Title and Summary View
Jan 6, 2010 SUMMIT, N.J., Jan 06, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 28th Annual JPMorgan Healthcare Conference on Monday, January 11, 2010 at 8:00 AM PST (11:00 AM EST) will be webcast live and will be available in the investor relations section of the company...
Jan 11, 2010 SUMMIT, N.J., Jan 11, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) 2009 Fourth Quarter Financial Results Year-Over-Year (Unaudited) Non-GAAP Total Revenue Increased More Than 20 Percent to Approximately $755 Million ...
Jan 12, 2010 BOUDRY, Switzerland, Jan 12, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that the Intergroupe Francophone du Myelome and University Hospital of Toulouse, the sponsor of the study, reported that the independent Data and Safety Monitoring Committee, of the international Phase III...
Jan 15, 2010 SUMMIT, N.J., Jan 15, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Under the terms of the merger ...
Jan 19, 2010 SUMMIT, N.J., Jan 19, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, January 28, 2010 at 9 a.m. ET to discuss the company's fourth quarter and full-year 2009 financial and operational results. The webcast will be available in t...
Jan 28, 2010 SUMMIT, N.J., Jan 28, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased 22 Percent to $758 Million; GAAP Total Revenue $...
Feb 25, 2010 SUMMIT, N.J., Feb 25, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an ove...
Mar 18, 2010 SUMMIT, N.J., Mar 18, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24, 2010 at 10:45 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web ...
Apr 19, 2010 SUMMIT, N.J., Apr 19, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, April 29, 2010 at 9 a.m. ET to discuss the company's first quarter 2010 financial and operational results. The webcast will be available in the investor ...
Apr 29, 2010 SUMMIT, N.J., Apr 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its senior management succession plan. As of the Company's annual meeting, scheduled on June 16, 2010, Dr. Sol J. Barer currently Chief Executive Officer, will be appointed Executive Chairman of the Board of Directors through December 31, 2010 and Rob...
Apr 29, 2010 SUMMIT, N.J., Apr 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG): 2010 First Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 31 Percent to $789 Million...
May 5, 2010 SUMMIT, N.J., May 05, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Ninth Annual JMP Securities Research Conference on Monday, May 10, 2010 at 9:30 a.m. PT will be webcast live and will be available in the investor relations section of the company's Web site at www.celge...
May 21, 2010 BOUDRY, Switzerland, May 21, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials evaluating Celgene products in blood cancers and solid tumors at the American Societ...
May 24, 2010 SUMMIT, N.J., May 24, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Citi Global Health Care Conference on Wednesday, May 26, 2010 at 11:00 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. ...
May 27, 2010 SUMMIT, N.J., May 27, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) announced that as a result of Barr Laboratories, Inc., withdrawing its Abbreviated New Drug Application (ANDA) for thalidomide with the US Food and Drug Administration, the US District Court for the District of New Jersey has granted the reque...
May 28, 2010 SUMMIT, N.J., May 28, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at three upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an over...
Jun 4, 2010 BOUDRY, Switzerland, Jun 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ:CELG) today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the ...
Jun 4, 2010 BOUDRY, Switzerland, Jun 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ:CELG) today announced researchersat the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma (DLBCL) either ...
Jun 5, 2010 BOUDRY, Switzerland, Jun 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced results of a Phase II study of pomalidomide and dexamethasone in multiple myeloma patients who have failed both lenalidomide and bortezomib. Data were presented by Dr. Martha Lacy of the Mayo Clinic during th...
Jun 6, 2010 BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either lenalidomide (REVLIMID), melphalan and prednisone (MPR) or melphalan plus autolog...
Jun 6, 2010 BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from a National Cancer Institute-sponsored clinical study were presented by representatives of a network of researchers led by the Cancer and Leukemia Group B (CALGB) at the annual meeting of the ...
Jun 6, 2010 BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from an Intergroupe Francophone du Myelome clinical study under the sponsorship of the University Hospital of Toulouse were presented at the American Society of Clinical Oncology. Results of the stu...
Jun 7, 2010 BOUDRY, Switzerland, Jun 07, 2010 (BUSINESS WIRE) --ABSTRACT #6508 Celgene International Sàrl (NASDAQ:CELG) today announced thatresearchers presented data from an investigator-initiated Phase II study of lenalidomide (REVLIMID) in untreated patients with chronic lymphocytic leukemia at the ann...
Jun 12, 2010 BOUDRY, Switzerland, Jun 12, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with new...
Jun 14, 2010 SUMMIT, N.J., Jun 14, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overvi...
Jun 24, 2010 (June 24, 2010) – Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan’s Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients with relapsed or refract...
Jun 30, 2010 SUMMIT, N.J. & LOS ANGELES, Jun 30, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG)and Abraxis BioScience Inc. (Nasdaq: ABII) today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merg...
Jul 19, 2010 SUMMIT, N.J., Jul 19, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 29, 2010 at 9 a.m. ET to discuss the company's second quarter 2010 financial and operational results. The webcast will be available in the inv...
Jul 29, 2010 SUMMIT, N.J., Jul 29, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2010 Second Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 36 Percent to $850 Million; GAA...
Aug 4, 2010 SUMMIT, N.J., Aug 04, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that it has received verbal confirmation of early termination of the Hart-Scott-Rodino Act (HSR) 30-day waiting period without the United States Federal Trade Commission (FTC) requesting additional information with regar...
Aug 20, 2010 BOUDRY, Switzerland, Aug 20, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) a...
Aug 25, 2010 SUMMIT, N.J., Aug 25, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVL...
Aug 26, 2010 SUMMIT, N.J., Aug 26, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) todayannounced the appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer, effective September 27, 2010. Ms. Fouse will be responsible for all finance operations at Celgene and will report t...
Sep 3, 2010 SUMMIT, N.J., Sep 03, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). The application requests authorization ...
Sep 8, 2010 SUMMIT, N.J., Sep 08, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentations at four upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at http://www.celgene.com. Celgene management...
Sep 15, 2010 SUMMIT, N.J., Sep 15, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the UBS 2010 Global Life Sciences Conference on Monday, September 20, 2010 at 10:30 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web sit...
Sep 24, 2010 SUMMIT, N.J., Sep 24, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the JMP Securities Fifth Annual Healthcare Conference on Tuesday, September 28, 2010 at 1:30 p.m. ET will be webcast live and will be available in the investor relations section of the company'...
Oct 4, 2010 SUMMIT, N.J., Oct 04, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity...
Oct 5, 2010 SUMMIT, N.J., Oct 05, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $1.25 billion. Of these notes, $500 million will mature in October 2015 and will bear interest at an annual rate of ...
Oct 13, 2010 SUMMIT, N.J. & LOS ANGELES, Oct 13, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) and Abraxis Bioscience, Inc. (NASDAQ: ABII) today announced that Abraxis' shareholders approved the merger agreement between the companies. The companies anticipate the closing of the transaction will occur on October ...
Oct 15, 2010 SUMMIT, N.J., Oct 15, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR...
Oct 18, 2010 SUMMIT, N.J., Oct 18, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, October 28, 2010 at 9 a.m. ET to discuss the company's third quarter 2010 financial and operational results. The webcast will be available in the i...
Oct 28, 2010 SUMMIT, N.J., Oct 28, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG): 2010 Third Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 31 Percent to $908 Million...
Oct 29, 2010 SUMMIT, N.J., Oct 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at Oppenheimer's 21st Annual Healthcare Conference on Tuesday, November 2, 2010 at 11:25 a.m. ET will be webcast live and will be available in the investor relations section of the ...
Nov 9, 2010 SUMMIT, N.J., Nov 09, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at ...
Nov 26, 2010 SUMMIT, N.J., Nov 26, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 22nd Annual Piper Jaffray Health Care Conference on Tuesday, November 30, 2010 at 9:00 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at ...
Nov 30, 2010 BOUDRY, Switzerland, Nov 30, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials in more than 260 posters and presentations, including more than 65 oral presentations evaluating Celgene ...
Dec 4, 2010 BOUDRY, Switzerland, Dec 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma...
Dec 4, 2010 BOUDRY, Switzerland, Dec 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the use of REVLIMID® (lenalidomide) either with rituximab or following a rituximab-containing ...
Dec 5, 2010 BOUDRY, Switzerland, Dec 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX®) in progressive or relapsed PTCL following prior ...
Dec 5, 2010 BOUDRY, Switzerland, Dec 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from a National Cancer Institute-sponsored clinical study were presented by representatives of a network of researchers led by the Cancer and Leukemia Group B (CALGB) at the 52nd A...
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that its next IMiD® compound, pomalidomide, was evaluated in three separate investigational trials of patients with multiple myeloma who were relapsed or refractory after prior treatm...
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that updated data from an Intergroupe Francophone du Myelome clinical study under the sponsorship of the University Hospital of Toulouse were presented at the 52nd Annual Meeting of the American Society of Hematology....
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing...
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomised, double-blind study of continuous REVLIMID® ...
Dec 7, 2010 BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the combination of REVLIMID® (lenalidomide) plus rituximab in indolent non-Hodgkin's lymphoma (NHL) were presented at the 52nd Annual Meeting of the American ...
Dec 7, 2010 BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG)today announced updated results from a retrospective analysis of a randomised, international phase III study of REVLIMID® (lenalidomide) for the treatment of patients with low/int-1 risk myelodysplast...
Dec 7, 2010 BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG)today announced the results of a comparative study evaluating the impact of REVLIMID® (lenalidomide) on the risk of progression to acute myeloid leukaemia (AML) in patients with low/int-1 risk myelody...
Dec 13, 2010 SUMMIT, N.J., Dec 13, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 2010 Deutsche Bank BioFEST on Wednesday, December 15, 2010 at 8:30 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene manag...
Dec 30, 2010 SUMMIT, N.J., Dec 30, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management w...
Jan 4, 2011 BOUDRY, Switzerland, Jan 04, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin). The company submitted a Marketing Authorisation Application (MAA) for the app...
Jan 10, 2011 SUMMIT, N.J., Jan 10, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG): 2010 Fourth Quarter Financial Results Year-Over-Year (Unaudited) Non-GAAP Total Revenue Increased Approximately...
Jan 19, 2011 SUMMIT, N.J., Jan 19, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, January 27, 2011 at 9 a.m. ET to discuss the company's fourth quarter and full year 2010 financial and operational results. The webcast will be ava...
Jan 27, 2011 SUMMIT, N.J., Jan 27, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG): 2010 Fourth Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 38 Percent to $1.05 Billi...
Feb 9, 2011 SUMMIT, N.J., Feb 09, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at ISI Group's 1st Annual Global Positioning Summit on Monday, February 14, 2011 at 10:00 a.m. ET will be webcast live and will be available in the investor relations section of the ...
Feb 16, 2011 SUMMIT, N.J., Feb 16, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced the election of Michael A. Friedman, MD, to its Board of Directors. Dr. Friedman is an experienced healthcare leader with a distinguished career in oncology research, regulatory strategy and public healthcare policy. He ...
Feb 16, 2011 SUMMIT, N.J., Feb 16, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that the company's Board of Directors has authorized the repurchase of up to an additional $1 billion of the Company's common stock through December 2012. This authorization is in addition to the $500 million authorizati...
Feb 16, 2011 BOUDRY, Switzerland, Feb 16, 2011 (BUSINESS WIRE) --Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (Nasdaq:CELG) today announced that the National Institute for Health and Clinical Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending VIDAZA within its li...
Feb 24, 2011 SUMMIT, N.J., Feb 24, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Citi 2011 Global Health Care Conference on Tuesday, March 1, 2011 at 1:30 p.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at ...
Feb 28, 2011 SUMMIT, N.J., Feb 28, 2011 (BUSINESS WIRE) --Celgene Corporation (Nasdaq:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review classification to its Supplemental New Drug Application (sNDA) regarding ISTODAX (romidepsin) for injection for the treatment of peripheral T-ce...
Mar 3, 2011 SUMMIT, N.J., Mar 03, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Cowen and Company 31st Annual Health Care Conference on Wednesday, March 9, 2011 at 10:15 a.m. ET will be webcast live and will be available in the investor relations section of ...
Mar 10, 2011 SUMMIT, N.J., Mar 10, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at Barclays Capital 2011 Global Healthcare Conference on Tuesday, March 15, 2011 at 1:30 p.m. ET will be webcast live and will be available in the investor relations section of the company's Web s...
Apr 13, 2011 SUMMIT, N.J., Apr 13, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, April 28, 2011 at 9 a.m. ET to discuss the company's first quarter 2011 financial and operational results. The webcast will be available in the inv...
Apr 27, 2011 SUMMIT, N.J., Apr 27, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at ...
Apr 28, 2011 SUMMIT, N.J., Apr 28, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG): 2011 First Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 40 Percent to $1.11 Billio...
May 3, 2011 SUMMIT, N.J., May 03, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced senior management will host a live webcast on Thursday, May 5, 2011 at 1 p.m. ET to discuss data presented at the International Myeloma Workshop in Paris. The webcast will be available in the investor relations se...
May 5, 2011 BOUDRY, Switzerland, May 05, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that updated data from a National Cancer Institute-sponsored clinical study were presented by representatives of a network of researchers led by the Cancer and Leukemia Group B (CALGB) at the 2011 Internatio...
May 6, 2011 BOUDRY, Switzerland, May 06, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced data from multiple phase III studies evaluating the benefit/risk profile of REVLIMID were presented during the International Myeloma Workshop in Paris, France. The updated res...
Jun 4, 2011 BOUDRY, Switzerland, Jun 04, 2011 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that final results from a phase III study of ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) in combination with carboplatin in patients with advanced non-small cell lung cancer ...
Jun 5, 2011 BOUDRY, Switzerland, Jun 05, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced results from a phase II investigator initiated study of REVLIMID (lenalidomide) in combination with Avastin (bevacizumab), docetaxel and prednisone in patients with metastatic castration-resista...
Jun 6, 2011 BOUDRY, Switzerland, Jun 06, 2011 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that results from an investigator-initiated phase II study of ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), gemcitabine and bevacizumab as first-line treatment in metastatic b...
Jun 6, 2011 BOUDRY, Switzerland, Jun 06, 2011 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that results from two investigator initiated studies including ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), and bevacizumab in unresectable melanoma were presented at the 201...
Jun 16, 2011 SUMMIT, N.J., Jun 16, 2011 (BUSINESS WIRE) --Celgene Corporation (Nasdaq:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for its Supplemental New Drug Application (sNDA) for an additional indication for ISTODAX (romidepsin) for injection for the treatment of p...
Jun 16, 2011 BOUDRY, Switzerland, Jun 16, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP* chemotherapy (R2CHOP) in patients with unt...
Jun 16, 2011 BOUDRY, Switzerland, Jun 16, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from a Phase I/II study evaluating the combination of REVLIMID® (lenalidomide) plus rituximab (R2) in relapsed/refractory mantle...
Jun 17, 2011 BOUDRY, Switzerland & LYON, France, Jun 17, 2011 (BUSINESS WIRE) --Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene International Sarl (Nasdaq: CELG) today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID (lenalidomide)/ritux...
Jun 17, 2011 BOUDRY, Switzerland, Jun 17, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID (lenalidomide) plus rituximab (R2...
Jul 13, 2011 SUMMIT, N.J., Jul 13, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 28, 2011 at 9 a.m. ET to discuss the Company's second quarter 2011 financial and operational results. The webcast will be available in the inv...
Jul 28, 2011 SUMMIT, N.J., Jul 28, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG): 2011 Second Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 38 Percent to $1.18 Billi...
Aug 4, 2011 SUMMIT, N.J., Aug 04, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 2011 Canaccord Genuity Growth Conference on Thursday, August 11, 2011 at 11:30 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site...
Aug 18, 2011 SUMMIT, N.J., Aug 18, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) announced the Company's Board of Directors has authorized the repurchase of up to an additional $2 billion of the Company's common stock. "The expansion of the share repurchase program reflects our confidence in the o...
Aug 31, 2011 SUMMIT, N.J., Aug 31, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) announced its presentations at three upcoming investor conferences will be webcast live and will be available in the investor relations section of the Company's Web site at ...
Sep 14, 2011 SUMMIT, N.J., Sep 14, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the Company's Web site at ...
Sep 21, 2011 SUMMIT, N.J., Sep 21, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at JMP Securities Healthcare Conference 2011 on Tuesday, September 27, 2011 at 11:30 a.m. ET will be webcast live and will be available in the investor relations section of the Company's Web site ...
Oct 6, 2011 Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG) today announced, that it is rectifying information in its press release of September 23rd, 2011 to provide more complete information on the observed risk of cancer and recommended changes to the product label for REVLIMID in the E...
Oct 6, 2011 BOUDRY, Switzerland, Oct 06, 2011 (BUSINESS WIRE) -- Celgene International Sàrl (Nasdaq:CELG) today announced that results from a clinical study of ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer were published in an...
Oct 12, 2011 SUMMIT, N.J., Oct 12, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, October 27, 2011 at 9 a.m. ET to discuss the Company's third quarter 2011 financial and operational results. The webcast will be available in the i...
Oct 27, 2011 SUMMIT, N.J., Oct 27, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) reported Non-GAAP net product sales of $1,218 million for the third quarter of 2011, a 38 percent increase from the same period in 2010. Non-GAAP net income for the third quarter of 2011 increased 34 percent to $469 million compared to ...
Nov 3, 2011 SUMMIT, N.J., Nov 03, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Credit Suisse 2011 Healthcare Conference on Friday, November 11, 2011 at 11:30am ET will be webcast live and will be available in the investor relations section of the company's Web site at...
Nov 8, 2011 BOUDRY, Switzerland, Nov 08, 2011 (BUSINESS WIRE) --Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced data from a Phase II study of apremilast, its investigational oral immunomodulatory compound, in patients with ankylosing spondylitis (AS) were presented at the Am...
Nov 21, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 21, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG) today announced that REVLIMID (lenalidomide) has been granted approva...
Nov 22, 2011 BOUDRY, Switzerland, Nov 22, 2011 (BUSINESS WIRE) --Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG) announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL®...
Nov 25, 2011 SUMMIT, N.J., Nov 25, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Piper Jaffray Health Care Conference 2011 on Tuesday, November 29, 2011 at 11 a.m. EST will be webcast live and will be available in the investor relations section of the Company's Web site...
Dec 10, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 10, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:CELG), announced results from a multi-center Phase I study that...
Dec 11, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced interim results of CLL-009, a study evaluating three starti...
Dec 11, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) announced results from a retrospective analysis to assess the risk of ...
Dec 12, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 12, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today reported final results from the phase II p...
Dec 12, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 12, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced that its oral therapy pomalidomide was evaluated as a ...
Dec 12, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 12, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation (Nasdaq:CELG) announced data from a sub-analysis of a Phase II, multicenter, internat...
Dec 12, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 12, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced that data from the planned interim analysis of MM-015, a ph...
Dec 13, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 13, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evalua...
Dec 13, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 13, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced that updated data evaluating continuous treatment wi...
Dec 13, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 13, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced results from an investigational study evaluating REVLIMID (...
Dec 14, 2011 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 14, 2011-- Celgene International Sàrl (Nasdaq: CELG) and the Groupe d’Etude des Lymphomes de l’Adulte (GELA) today announced the organizations have ...
Dec 22, 2011 SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 22, 2011-- Celgene Corporation (NASDAQ: CELG) today announced the appointment of Richard Bagger as Senior Vice President, Corporate Affairs and St...
Dec 28, 2011 SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 28, 2011-- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in ...
Jan 9, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 9, 2012-- Celgene Corporation (NASDAQ: CELG) today reviewed 2011 achievements and provided its outlook for 2012 at the JPMorgan 30th Annual Healthca...
Jan 23, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 23, 2012-- Celgene Corporation (NASDAQ: CELG) today announced the election of Richard W. Barker, D.Phil., to its Board of Directors. Dr. Barker is a global thought leader in healthcare systems and government policy. He served as Director ...
Jan 26, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 26, 2012-- Celgene Corporation (NASDAQ: CELG) reported Non-GAAP net product sales of $1,241 million for the fourth quarter of 2011, a 21 percent increase f...
Jan 26, 2012 SUMMIT, N.J. and BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 26, 2012-- Celgene Corporation (NASDAQ: CELG) and Avila Therapeutics, Inc., a priva...
Feb 21, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 21, 2012-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Citi 2012 Global Health Care Conference on Tuesday, Februar...
Feb 27, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 27, 2012-- Celgene Corporation (NASDAQ: CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor ...
Mar 8, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 8, 2012-- Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Avila Therapeutics. Celgene...
Apr 17, 2012 SUMMIT, N.J., Apr 17, 2012 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, April 26, 2012 at 9 a.m. ET to discuss the company's first quarter 2012 financial and operational results. The webcast will be available in the investor...
Apr 26, 2012 SUMMIT, N.J., Apr 26, 2012 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) reported Non-GAAP net product sales of $1,245 million for the first quarter of 2012, a 17 percent increase from the same period in 2011. Non-GAAP net income for the first quarter of 2012 increased 23 percent to $484 million compared to $393 mi...
May 4, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--May. 4, 2012-- Celgene Corporation (NASDAQ: CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor r...
May 7, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--May. 7, 2012-- Celgene Corporation (NASDAQ: CELG) today announced the appointment of Thomas M. Moriarty as General Counsel and Corporate Secretary. In this po...
May 10, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--May. 10, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from three phase III studies evaluating ...
May 22, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--May. 22, 2012-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at Sanford C. Bernstein’s 28th Annual Strategic Decisions Conf...
Jun 2, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 2, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:CELG) today announced results from multiple presentations evaluating ABRAXANE...
Jun 2, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 2, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from a randomized study comparing REVLIMID®...
Jun 4, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 4, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced results from a study of ABRAXANE® (pacl...
Jun 6, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 6, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced a series of milestones related to the development of AB...
Jun 13, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 13, 2012-- Celgene Corporation (NASDAQ: CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an addition...
Jun 21, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 21, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), is providing a regulatory update for REVLIMID (lenalidomide) and poma...
Jul 12, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Jul. 12, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced top-line results from the PALACE-1 study, the first of...
Jul 16, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Jul. 16, 2012-- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 26, 2012 at 9 ...
Jul 20, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Jul. 20, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced it will request a re-examination of the negative opini...
Jul 26, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Jul. 26, 2012-- Celgene Corporation (NASDAQ: CELG) reported total revenue of $1,367 million for the second quarter of 2012, a 16 percent increase from the same ...
Aug 6, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 6, 2012-- Celgene Corporation (NASDAQ: CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf r...
Aug 7, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 7, 2012-- Celgene Corporation (NASDAQ: CELG) today announced the successful pricing of two series of senior unsecured notes for an aggregate principal amount of ...
Aug 27, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 27, 2012-- Celgene Corporation (NASDAQ: CELG) announced its presentations at four upcoming investor conferences will be webcast live and will be available in the investor...
Sep 6, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Sep. 6, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that statistical significance for the primary endpoint ...
Sep 19, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Sep. 19, 2012-- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will h...
Oct 2, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Oct. 2, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced results of its phase III, randomized, international stu...
Oct 3, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 3, 2012-- Celgene Corporation (NASDAQ: CELG) today announced it was notified by the U.S. Food and Drug Administration (FDA) that there will not be an ...
Oct 8, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 8, 2012-- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, October 25, 2012 at ...
Oct 12, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 12, 2012-- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE® (paclitaxe...
Oct 23, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Oct. 23, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III, multi-center, randomized, open-lab...
Oct 25, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 25, 2012-- Celgene Corporation (NASDAQ: CELG) reported total revenue of $1,419 million for the third quarter of 2012, a 14 percent increase from the same p...
Oct 25, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Oct. 25, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that abstracts for the upcoming Society for Melan...
Nov 7, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 7, 2012-- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the in...
Nov 9, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 9, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III study of ABRAXANE® (...
Nov 13, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 13, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today presented the results from PALACE-1, the Company’s first P...
Nov 27, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 27, 2012-- Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from rec...
Nov 28, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 28, 2012-- Celgene Corporation (NASDAQ: CELG) today announced its presentations at an upcoming investor conference and at the 54th American Society o...
Dec 10, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 10, 2012-- Celgene International Sàrl (NASDAQ: CELG) today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (...
Dec 10, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 10, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that data from a phase I study of oral, epigenetic ther...
Dec 11, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced data from its phase III, multi-center, randomized (2:1), op...
Dec 11, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2012-- Celgene International Sàrl (NASDAQ: CELG) today announced results from the “EMERGE” study (MCL-001), a phase II, multi-center, single-arm trial ...
Dec 11, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2012-- Celgene International Sàrl (NASDAQ: CELG) today announced results from an analysis of post-progression outcomes in MM-015, a phase III study of continuous...
Dec 11, 2012 BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced results from several studies evaluating combination treatment...
Dec 21, 2012 SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 21, 2012-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 31st Annual J.P. Morgan Healthcare Conference on Janu...
Jan 7, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 7, 2013-- Celgene Corporation (NASDAQ: CELG) provided its financial outlook for 2013 at the JPMorgan 31st Annual Healthcare Conference. In 2013, tot...
Jan 7, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Jan. 7, 2013-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that statistical significance for the primary endpoint...
Jan 22, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Jan. 22, 2013-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that its phase III clinical trial of ABRAXANE®...
Jan 24, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 24, 2013-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $1,416 million for the fourth quarter 2012, a 14 percent increase from the same ...
Feb 4, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 4, 2013-- Celgene Corporation (NASDAQ: CELG) plans to present at three upcoming investor conferences. The conferences will be webcast live and will be available in the In...
Feb 8, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 8, 2013-- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST® brand ...
Feb 11, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Feb. 11, 2013-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that REVLIMID® (lenalidomide) has been ...
Feb 20, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 20, 2013-- Celgene Corporation (NASDAQ: CELG) announced today that it has entered into an accelerated share repurchase (ASR) agreement with an investment bank to repurcha...
Feb 27, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Feb. 27, 2013-- EURORDIS (The European Organisation for Rare Diseases) announced today that Celgene Corporation (NASDAQ:CELG) has been awarded the prestigious ...
Feb 28, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 28, 2013-- Celgene Corporation (NASDAQ: CELG) plans to present at two upcoming investor conferences. The conferences will be webcast live and will be available in the Investor Relations section of the Company’s Web si...
Mar 2, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Mar. 2, 2013-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today presented the results from ESTEEM 1, the Company’s first ph...
Apr 3, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 3, 2013-- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, April 25, 2013 at 9 ...
Apr 25, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 25, 2013-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $1,429 million for the first quarter of 2013, a 15 percent increase from the sa...
Apr 26, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Apr. 26, 2013-- Celgene International Sàrl (NASDAQ: CELG) today announced the European Medicines Agency’s (EMA): Committee for Medicinal Products for Human Use...
Apr 29, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 29, 2013-- Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences in May. The conferences will be webcast live and the webcasts will be...
May 6, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--May. 6, 2013-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that statistical significance was achieved for the prim...
May 23, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--May. 23, 2013-- Celgene International Sàrl, a subsidiary of Celgene Corporation (Celgene) (NASDAQ: CELG) today announc...
May 31, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--May. 31, 2013-- Celgene Corporation (NASDAQ: CELG), announced today the initiation of the “Innovation Impact” Awards to recognize effective, innovative and succe...
May 31, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--May. 31, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency’...
Jun 3, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 3, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced updated data from MM-003, the CompanyR...
Jun 3, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 3, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced data from a study comparing melphalan, pr...
Jun 3, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 3, 2013-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced several analyses of a phase III clinical trial of ABRAXANE...
Jun 5, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 5, 2013-- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental new ...
Jun 6, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 6, 2013-- Celgene Corporation (NASDAQ: CELG) plans to present at an upcoming investor conference this month. The conference will be webcast live and the webcast will be a...
Jun 12, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 12, 2013-- Celgene Corporation (NASDAQ: CELG) announced today that its Board of Directors authorized the repurchase of up to an additional $3.0 billion...
Jun 12, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 12, 2013-- ABSTRACT #LB0001 Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced 52-week ...
Jun 13, 2013 ABSTRACT #SAT0299; OP0104; SAT0280 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 13, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today anno...
Jun 14, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 14, 2013-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today presented results from a randomized, placebo-controlled phase II...
Jun 17, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 17, 2013-- Celgene International Sàrl (NASDAQ: CELG) was today notified that the European Commission (EC) has amended the marketing authorisation for REVL...
Jun 20, 2013 ABSTRACTS #063, 213 BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 20, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results f...
Jun 26, 2013 MorphoSys will hold a conference call on Thursday, June 27, at 4:00pm CEST (3:00pm GMT/10:00am EDT) Celgene secures worldwide rights to MOR202, whereby the companies will jointly develop MOR202 globally and co-promote the product in Europe MorphoSys retains a 50/50 profit sharing in its co-promo...
Jul 8, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Jul. 8, 2013-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, July 25, 2013 at 9 a.m. ET to ...
Jul 11, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Jul. 11, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that its phase III study (MM-020/IFM 07-...
Jul 18, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Jul. 18, 2013-- Celgene Corporation (NASDAQ: CELG) today announced that after consultation with the U.S. Food and Drug Administration (FDA) ...
Jul 25, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Jul. 25, 2013-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $1,564 million for the second quarter of 2013, a 17 percent increase from the same p...
Aug 1, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 1, 2013-- Celgene Corporation (NASDAQ: CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf regist...
Aug 1, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Aug. 1, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that data evaluating treatment with REVLIMID...
Aug 2, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 2, 2013-- Celgene Corporation (NASDAQ: CELG) today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of ...
Aug 9, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Aug. 9, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that the European Commission (EC) ha...
Aug 28, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 28, 2013-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences in September. The conferences will be webcast live and the webcast will be a...
Sep 5, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Sep. 5, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that updated results from MM-003, a phase III m...
Sep 6, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Sep. 6, 2013-- Celgene Corporation (NASDAQ: CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental ...
Sep 26, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Sep. 26, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the latest research findings on apr...
Oct 1, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 1, 2013-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, October 24, 2013 at 9 a.m. ET to d...
Oct 3, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Oct. 3, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of pre-specified sub-analyses from...
Oct 16, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Oct. 16, 2013-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced the results of the MPACT (Meta...
Oct 24, 2013 SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 24, 2013-- Celgene Corporation (NASDAQ:CELG) reported third quarter 2013 total revenue of $1,674 million compared to $1,419 million in the third ...
Oct 28, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned su...
Oct 29, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned su...
Nov 7, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned su...
Nov 22, 2013 BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned su...
Dec 7, 2013 ASH 2013 BOUDRY, Switzerland--(...
Dec 9, 2013 ASH 2013 BOUDRY, Switzerland--(...
Dec 10, 2013 ASH 2013 BOUDRY, Switzerland--(...
Dec 10, 2013 ASH 2013 BOUDRY, Switzerland--(...
Jan 2, 2014 SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that it...
Jan 7, 2014 BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned su...
Jan 10, 2014 SUMMIT, N.J.--(BUSINESS WIRE)--During the 32nd Annual J.P. Morgan Healthcare ...
Jan 13, 2014 SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) provided its preliminar...
Jan 21, 2014 LOS ANGELES, Calif. and SUMMIT, N.J. - January 21, 2014 - Pancreatic cancer is one of the deadliest cancers in the United States, with a five year survival rate of just six percent.1 Now, a new survey has found that only 19 percent of people diagnosed with pancreatic cancer ever discussed the possibility of participatin...
Jan 22, 2014 SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) will host a conf...
Jan 30, 2014 2013 Total Revenue of $6.5 Billion, Increased 18 Percent Y/Y; 2013 Total Net Product Sales of $6.4 Billion, Increased 18 Percent Y/Y 2013 Adjusted Diluted Earnings per Share of $5.96, Increased 21 Percent Y/Y; 2013 GAAP Diluted Earnings per Share of $3.37, Increased 2 Percent Y/Y ...
Feb 11, 2014 POMALYST Is A New Option For Patients Whose Disease Has Progressed Despite Treatment With Available Therapies MISSISSAUGA, ON, Feb. 11, 2014 /CNW/ - Health Canada has approved POMALYST™ oral therapy (pomalidomide capsules) in combination with dexamethasone, for patients with multiple myeloma for whom both lenalidomi...
Feb 11, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at three upcoming investor conferences. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Co...
Feb 13, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) announced that the Board of Directors voted to recommend a two-for-one split of the Company's common stock to be effected through an Amendment to the Company's Certificate of Incorporation. "This recommendation reflects our...
Mar 19, 2014 Results from European Pancreatic Cancer Index reinforce critical need for action, including more research to help drive improved care BOUDRY, Switzerland--(BUSINESS WIRE)-- With pancreatic cancer poised to become the third leading cause of cancer death in Europe, Celgene International Sà...
Mar 20, 2014 Survey provides a unique and comprehensive look at patient quality of life Nearly half of psoriasis patients surveyed had not seen a doctor in the past year and two-thirds of psoriatic arthritis patients surveyed were not receiving medical treatment for their condition Res...
Mar 21, 2014 In phase III studies, OTEZLA demonstrated clinically significant improvements across multiple manifestations of psoriatic arthritis and a consistent safety profile Routine laboratory monitoring for patients taking OTEZLA is not required OTEZLA is an oral therapy that modul...
Mar 23, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (CELG) today released new research findi...
Mar 23, 2014 OTEZLA demonstrated stable improvements in PASI response up to week 52 in ESTEEM 1 OTEZLA significantly improved signs and symptoms of psoriasis, including scalp and nails, compared with placebo in ESTEEM 2 at week 16, consistent with previously-reported ESTEEM 1 data Long...
Apr 1, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 24, 2014 at 9 a.m. ET to discuss first quarter 2014 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Apr 24, 2014 - GED-0301 is a First-in-Class, Oral Antisense Drug Targeting Smad7 mRNA - Phase III Program for Crohn's Disease Targeted to Begin by Year-End 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) entered into a global license agreement with...
Apr 24, 2014 REVLIMID® for Newly Diagnosed Multiple Myeloma Submitted in U.S. and EU Late-stage product acquisition of GED-0301 from Nogra Pharma Ltd 2014 Adjusted Diluted EPS and Net Product Sales Guidance Affirmed SUMMIT, N.J.--(BUSINESS WIRE...
Apr 25, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at four upcoming investor conferences in the month of May. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section...
May 6, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity da...
May 7, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $2,500 million. Of these notes, $500 million will mature in 2019 and will bear interest at an annual rate of 2.250 percen...
May 14, 2014 BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced more than 65 abstracts reporting on investigational studies in blood and solid tumor cancers will be presented during the 50th American Society of Clinic...
May 20, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at three upcoming investor conferences in the month of June. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations ...
May 22, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced organizational changes that will go into effect on August 1, 2014. Mark Alles is promoted to President and Chief Operating Officer (COO) Jacqualyn Fouse, PhD, is promoted to Presiden...
Jun 1, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced updated Overall Survival (OS) results from a post-hoc analysis of its phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of ABRAXANE® (paclitaxel protein-bound particles for injectable suspens...
Jun 11, 2014 Clinically meaningful improvements in enthesitis, dactylitis and physical function with OTEZLA seen at week 16 and were sustained for up to 52 weeks of treatment PALACE 4 is the first and only large randomized, placebo-controlled study to examine the efficacy and safety of a single agent in patien...
Jun 11, 2014 Clinically meaningful improvements in measures of disease activity with OTEZLA seen at week 16 and were sustained for up to 52 weeks of treatment OTEZLA demonstrated a consistent safety profile with no clinically meaningful changes in laboratory measurements across three PALACE phase III ...
Jun 14, 2014 Two phase 2 programs show activity in transfusion dependent and non-transfusion dependent beta-thalassemia patients SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced interim data from two studies of ...
Jun 19, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that its stockholders approved a two-for-one stock split and an increase from 575 million to 1,150 million in the number of authorized shares of the Company's common stock at the Company's Annual Meeting of Stockholders on June 18, ...
Jun 26, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- It is with great sadness that Celgene Corporation (NASDAQ:CELG) announces the death of Rodman L. Drake, a member of its Board of Directors since 2006. "We are deeply saddened by the passing of Rod Drake," said Bob Hugin, Chairman and Chief Executive Officer...
Jul 1, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, July 24, 2014 at 9 a.m. ET to discuss second quarter 2014 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Jul 9, 2014 Phase III POSTURE Study Did Not Achieve Primary Endpoint of ASAS 20 at Week 16 Based on Efficacy and Safety Data at Week 24, the Independent Data Monitoring Committee Recommended Continuation of the Phase III POSTURE Study Without Change In OTEZLA Study Arms, ASAS 20 Resul...
Jul 24, 2014 - 2014 Total Revenue, Net Product Sales and Adjusted Diluted EPS Guidance Raised - Data on GED-0301, MDS-005 and MCL-002 to be Presented H2 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported net product sales of $1,845 million for the sec...
Aug 19, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell ...
Aug 20, 2014 (NEW YORK and SUMMIT, NJ - August 20, 2014) - Bristol-Myers Squibb Company (NYSE: BMY) and Celgene Corporation (Nasdaq: CELG) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb's investigational PD-1 immune checkpoint i...
Aug 21, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at two upcoming investor conferences in the month of September. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations se...
Sep 4, 2014 Study met primary endpoint as significant progression-free survival benefit was seen for patients treated with continuous REVLIMID plus dexamethasone compared with those treated with a standard of care SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that dat...
Sep 23, 2014 In phase III studies, OTEZLA resulted in significant and clinically meaningful improvements in plaque psoriasis OTEZLA demonstrated a consistent safety and tolerability profile across clinical trials SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) ...
Oct 1, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 23, 2014 at 9 a.m. ET to discuss third quarter 2014 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Oct 7, 2014 BOUDRY, Switzerland - (7 October, 2014) - Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the latest research findings on OTEZLA® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), in plaque psoriasis and psoriatic arthritis will be pre...
Oct 10, 2014 Apremilast treatment resulted in improved health-related quality of life during 16 weeks of therapy in ESTEEM 2 Apremilast significantly increased work productivity and improved work limitations compared with placebo at week 16 in pooled analyses of ESTEEM 1 and 2 BO...
Oct 10, 2014 Apremilast significantly improved preexisting scalp, nail, and palmoplantar psoriasis at week 16 in ESTEEM 2 Improvements in pruritus (itching) seen as early as week 2 in analyses of ESTEEM 1 and 2 and maintained through week 32 Improvement in mean PASI scores achieved with apremil...
Oct 20, 2014 BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of GED-0301 in 166 patients with active Crohn's disease will be presented at the ...
Oct 23, 2014 - 2014 Total Revenue and Adjusted Diluted EPS Guidance Raised - Phase II Data on GED-0301 Presented at United European Gastroenterology Week - Over 170 Abstracts Highlighting Celgene Products and Research at Major Medical Meetings Expected by Year-End ...
Oct 31, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences, where Celgene management will provide an overview of the Company, and at the 56th American Society of Hematology (ASH) annual meeting in December. The conferences and ASH event will be ...
Nov 6, 2014 Presentations will focus on a wide range of disease areas including multiple myeloma, lymphomas, leukemias, myelodysplastic syndromes and beta-thalassemia SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that data from more than 160 abstracts, includ...
Nov 13, 2014 Celgene Joins Forces with Leading Patient Advocacy Organizations on World Pancreatic Cancer Day - 13 November 2014 - to Raise Awareness About this Major Cancer Killer SUMMIT, N.J.--(BUSINESS WIRE)-- While it may not be surprising that breast and lung cancers are top of mind when peo...
Nov 18, 2014 ACR 20 response rates sustained with continued OTEZLA treatment through 104 weeks - 65.3 percent and 61.4 percent in PALACE 1 and 4, respectively Eighty four percent of patients who completed one year of treatment with OTEZLA continued on OTEZLA through week 104 in both trials ...
Nov 21, 2014 BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl (NASDAQ: CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA® (apremilast), th...
Dec 1, 2014 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) received notice of an unsolicited "mini-tender" offer by TRC Capital Corporation to purchase up to 1,000,000 shares of Celgene's common stock, approximately 0.13% of outstanding shares, at $101.75 per share. TRC Capital's offer is 4.71% be...
Dec 7, 2014 Continuous REVLIMID® (lenalidomide) plus low-dose dexamethasone increased progression-free survival compared with fixed duration of Rd or melphalan, prednisone and thalidomide regardless of age, renal impairment, or depth of response SAN FRANCISCO--(BUSINESS WIRE)-- Celgene Cor...
Dec 8, 2014 Median duration of transfusion independence was 8.2 months SAN FRANCISCO--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced results from an international phase III study of REVLIMID® (lenalidomide) compared with placebo in patients with red-blood cell (RBC) transfusion...
Dec 8, 2014 Results of MCL-002 (SPRINT) study demonstrated significantly longer progression-free survival for lenalidomide compared to investigators' choice in relapsed/refractory MCL Combination of lenalidomide plus rituximab demonstrated 84.2% response rate in previously untreated MCL ...
Dec 8, 2014 Compared with conventional care regimens, VIDAZA doubled overall survival times in subsets of patients with poor-risk cytogenetics and in patients with morphologic dysplastic-related changes SAN FRANCISCO--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that data from two...
Dec 8, 2014 Exploratory analysis in heavily pre-treated patients, in response and survival measures were reported in hard-to-treat patients Phase III ROBUST study will evaluate REVLIMID plus R-CHOP in hard-to-treat patients SAN FRANCISCO--(BUSINESS WIRE)-- Celgene Corporation (N...
Dec 8, 2014 SAN FRANCISCO--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that results from the STRATUS™ trial (MM-010), a single-arm phase IIIb study of pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma were presented at the 56th American Society ...
Dec 9, 2014 SAN FRANCISCO--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that data were presented from a phase 1b/2 study of ISTODAX® (romidepsin) combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with peripheral t-cell lymphoma were presented during the 56t...
Dec 19, 2014 BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for continuous oral treatment wit...
Jan 6, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- During the 33rd Annual J.P. Morgan Healthcare Conference on January 12, 2015 at 10:30 a.m. ET, Celgene Corporation (NASDAQ:CELG) will present a business update on the Company in addition to unaudited 2014 financial results and an updated financial outlook. The presentation can be ...
Jan 12, 2015 2015 Guidance for Net Product Sales and Diluted EPS Preliminary 2014 Financial Results Including Net Product Sales and Diluted EPS Providing Financial Outlook for 2020; Net Product Sales Expected to Exceed $20B and Adjusted Diluted EPS Expected to Exceed $12.50 ...
Jan 16, 2015 BOUDRY, SWITZERLAND - (January 16th, 2015) - Celgene International Sàrl (NASDAQ: CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted marketing authorisation for OTEZLA® (apremilast), the company's oral selective inhibitor of phosphodiesterase 4 (PDE4), in two th...
Jan 23, 2015 In Europe, Lung Cancer is the 4th most commonly diagnosed cancer and the leading cause of cancer-related mortality BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced...
Jan 27, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.cel...
Jan 29, 2015 - Net Product Sales Exceeded $2B in Q4:14; Increased 19% Y/Y - 2015 Guidance and 2020 Financial Targets Provided - U.S. and EU Decisions on REVLIMID® NDMM Expected in Q1 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported o...
Feb 10, 2015 New decision by SMC makes ABRAXANE® available to all eligible pancreatic cancer patients in Scotland BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that ABRAXANE...
Feb 18, 2015 REVLIMID plus dexamethasone is now approved as an option for use in all patients with multiple myeloma SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID...
Feb 19, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.cel...
Feb 20, 2015 Oral REVLIMID is approved for treatment until disease progression BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved REVLIMID® (lenalidomi...
Mar 2, 2015 Nanotechnology Therapy Now Available for Patients in European Union with Lung Cancer BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approve...
Mar 18, 2015 65 percent of patients treated with GED-0301 160 mg once daily for two weeks achieved clinical remission at both day 15 and day 28, versus 10 percent of patients on placebo 72 and 67 percent of patients treated with 160 mg once daily were in clinical remission at day 28 and at day 84, respectively...
Mar 20, 2015 Third phase III study with OTEZLA to demonstrate statistically significant improvements versus placebo for the primary and key secondary endpoints at week 16 More patients achieved a PASI-75 response at week 32 than at week 16 for those randomized to OTEZLA at baseline and those switched from ...
Mar 20, 2015 Improvements in the severity of preexisting nail, scalp and palmoplantar psoriasis achieved at week 16 were maintained in OTEZLA responders through week 52 in ESTEEM 2 OTEZLA improved the severity of palmoplantar psoriasis at week 16 in a subset of patients across three trials ...
Apr 1, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the appointment of Gerald F. Masoudi as Executive Vice President, General Counsel and Corporate Secretary, effective June 1, 2015. Mr. Masoudi will be responsible for global legal strategy and will serve on the company's Ex...
Apr 1, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 30, 2015 at 9 a.m. ET to discuss first quarter 2015 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Apr 15, 2015 Summit, N.J. - (April 15, 2015) - Celgene Corporation (NASDAQ: CELG) today announced that results from a multicenter, randomized, placebo-controlled phase II trial (BCT-001) of apremilast (Otezla®) in patients with Behçet's disease were published in the April 16 issue of The New England Journal of Medicine. Behçet's disease is a ra...
Apr 15, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the election of Michael W. Bonney to its Board of Directors. Mr. Bonney served as Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals, Inc. from June 2003 until his retirement on December ...
Apr 15, 2015 Publication highlights safety and efficacy data, including disease-related quality of life measures, for apremilast in rare inflammatory disorder Global phase III clinical trial now enrolling patients SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) ...
Apr 23, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences and two upcoming medical congresses in May where Celgene management will provide an overview of the Company. The conferences will be webcast live and a link to the webcast will be ava...
Apr 23, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced it has fulfilled the accelerated approval requirements for POMALYST® (pomalidomide) based on results from MM-003, an international phase III study of POMALYST plus low-dose dexamethasone versus high-dose dexamethasone ...
Apr 24, 2015 Program to Focus Initially on Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes and Multiple Myeloma Studies Planned to Start in Second Half 2015 BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International II Sàrl, a wholly owned subsidiary of Celgene ...
Apr 27, 2015 Celgene Committed to Expanding Sustainable Pipeline of Life-Enhancing Medical Innovation to Benefit Cancer Patients Celgene Expects Acquisition to be Neutral to Adjusted Diluted Earnings in 2015 SUMMIT, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:...
Apr 30, 2015 REVLIMID® Net Product Sales of $1.34B; Increased 17% Y/Y Adjusted Diluted Earnings Per Share of $1.07, Increased 29% Y/Y; GAAP Diluted Earnings Per Share at $0.86 Portfolio and Platforms Strengthened By Strategic Deals with AstraZeneca, Quanticel and...
May 1, 2015 Patients achieving red-blood-cell transfusion independence of at least 8 weeks demonstrated significant improvements in all preselected domains Abstract #116 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced results from a pre...
May 13, 2015 Total of eight approved therapies and investigational agents being evaluated in 15 diseases SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced more than 55 presentations reporting on investigational studies in blood and solid tumor cancers will be pres...
May 19, 2015 Patients with more severe Crohn's disease or longer disease duration treated with GED-0301 160 mg experienced clinical remission and response rates greater than placebo SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that a post-hoc subgroup analys...
May 28, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences in June where Celgene management will provide an overview of the Company. The conferences will be webcast live and a link to the webcast will be available in the Investor Relations section of ...
Jun 3, 2015 New two-year pooled analysis of PALACE trials evaluated effects of OTEZLA on enthesitis and dactylitis in patients with active psoriatic arthritis Data assessed the impact of investigational compound CC-220 on levels of systemic lupus erythematosus-associated transcription factors ...
Jun 9, 2015 Study Abstract Reports OTEZLA (apremilast) Demonstrated Improvements at Week 52 in Enthesitis and Dactylitis Improvements in Enthesitis and Dactylitis at Week 52 Were Sustained Through Week 104 BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a...
Jun 12, 2015 BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced updated results of its pivotal phase III FIRSTTM (MM-020/IFM 07-01) trial, comparing continuous REVLIMID® (lenalidomide) plus low-dose dexamethasone ...
Jun 13, 2015 BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced two analyses of MCL-002 (SPRINT), its multi-center, open-label, phase II randomized trial comparing Revlimid® (lenalidomide) with investigators' choice ...
Jun 17, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $4.0 billion of the Company's common stock. This open-ended program is effective immediately. Purchases m...
Jun 29, 2015 Broad strategic collaboration leveraging combined immunology expertise and assets to develop and commercialize novel immunotherapies for the treatment of cancer and autoimmune diseases Celgene gains option to commercialize Juno programs outside North America and co-promote certain prog...
Jul 6, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, July 23, 2015 at 9 a.m. ET to discuss second quarter 2015 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Jul 14, 2015 Significantly Enhances Celgene's I&I Franchise with the Addition of Ozanimod, Potentially a Best-in-Class Oral Agent in Phase III Trials for Inflammatory Bowel Disease and Multiple Sclerosis Accelerates Growth Beginning in 2019; Significant Growth Driver Beyond 2020 with Expected Ozanimod Peak Ann...
Jul 23, 2015 REVLIMID® Net Product Sales $1,444 Million; Increased 19% Y/Y POMALYST®/IMNOVID® Net Product Sales $235 Million; Increased 46% Y/Y ABRAXANE® Net Product Sales $244 Million; Increased 13% Y/Y OTEZLA® ...
Jul 28, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that its direct wholly-owned subsidiary, Strix Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Receptos, Inc. (NASDAQ: RCPT) at a price of $232.00 per share, net to ...
Aug 3, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity da...
Aug 4, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of five series of senior unsecured notes for an aggregate principal amount of $8.0 billion. Of these notes, $1.0 billion will mature in 2018 and will bear interest at an annual rate of 2.125 percent, ...
Aug 11, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by its wholly-owned subsidiary, Strix Corporation, for all issued and ...
Aug 25, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Receptos, Inc. at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes, expired ...
Aug 26, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences in September where Celgene management will provide an overview of the Company. The conferences will be webcast live and a link to the webcast will be available in the Investor Relations sectio...
Aug 27, 2015 Significantly Enhances Celgene's I&I Franchise with the Addition of Ozanimod, Potentially a Best-in-Class Oral Agent in Phase III Trials for Inflammatory Bowel Disease and Multiple Sclerosis SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced it ...
Sep 25, 2015 Anticipated approval could provide new option for population with limited treatments Expanded indication brings medicine to elderly AML patients who are not eligible for haematopoietic stem cell transplantationand who have >30% myeloblasts in their bone marrow ...
Oct 1, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, November 5, 2015 at 9 a.m. ET to discuss third quarter of 2015 financial and operational results. The third quarter will include the financial and operational results of Receptos ...
Oct 9, 2015 New analyses of LIBERATE trial assess effect of OTEZLA or etanercept versus placebo on patient-reported itching (pruritus) and health-related quality of life Physician's Global Assessment and Body Surface Area (PGAxBSA) composite tool evaluated for the assessment of disease severity and r...
Oct 12, 2015 Improvements in PASI scores and disease-related quality of life observed at week 16 were maintained at week 52 in patients randomized to OTEZLA at baseline and in patients who switched from etanercept to OTEZLA at week 16 An exploratory analysis suggested improvements in itching observed at ...
Oct 16, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the election of Julia A. Haller, M.D., to its Board of Directors. Dr. Haller is Ophthalmologist-in-Chief of the Wills Eye Hospital in Philadelphia, PA where she holds the William Tasman, M.D. Endowed Chair. She serves as Pr...
Oct 19, 2015 A significantly greater proportion of patients with moderate to severe ulcerative colitis achieved clinical remission at 32 weeks with Ozanimod 1 mg versus placebo Clinical response and mucosal healing also significantly improved with Ozanimod 1 mg compared to placebo at week 32 ...
Oct 26, 2015 Oral Ozanimod TOUCHSTONE study in ulcerative colitis receives a UEGW Week top abstract prize BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today presented results from the maintenance phase of...
Oct 27, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at an upcoming investor conference, where Celgene management will provide an overview of the Company, and at the 57th American Society of Hematology (ASH) annual meeting in December. The conference and ASH event will be webcast ...
Oct 30, 2015 Expanded indication brings medicine to greater number of elderly AML patients who are not eligible for haematopoietic stem cell transplantation and have >30% myeloblasts in their bone marrow BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned ...
Nov 5, 2015 Over 150 Abstracts Expected at Medical Congresses in Fourth Quarter Completed Two Major Transactions in the Quarter: Receptos and Juno Therapeutics Key Drivers On-Track Supporting Industry-Leading Growth Including Acceleration of Mid- and Late-Stage Clinical Program...
Dec 5, 2015 Triplet regimen resulted in significantly improved progression-free survival compared to standard of treatment SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the addition of bortezomib to REVLIMID (lenalidomide) and low-dose dexamethasone (RVd), ...
Dec 6, 2015 Nearly 30 combination studies that include IMiD® compounds presented SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that nearly 30 combination studies including IMiD® compounds, REVLIMID® (lenalidomide) and POMALYST®/IMNOVID...
Dec 7, 2015 Program starting with four studies of durvalumab and combination therapies across multiple hematologic disorders SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and AstraZeneca (NYSE:AZN), today announced the initiation of the FUSION clinical development program of ...
Dec 9, 2015 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that multiple studies being presented at the San Antonio Breast Cancer Symposium will highlight the investigational use of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspensi...
Dec 21, 2015 BOUDRY, Switzerland & TOKYO--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally, has been granted full marketing authorization by Japan's Ministry of Hea...
Dec 22, 2015 Natco to Acquire License to Sell Generic Lenalidomide in the U.S. Without Volume Limitation commencing in late January, 2026 License Will Also Provide Natco With a Volume-Limited Entry Beginning in March, 2022 with Anticipated Mid-Single-Digit Percentage Of Capsules Sold In the First 1...
Jan 4, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- During the 34th Annual J.P. Morgan Healthcare Conference on January 11, 2016 at 10:30 a.m. ET, Celgene Corporation (NASDAQ:CELG) will present a business update on the Company in addition to unaudited 2015 financial results and an updated financial outlook. The presentation...
Jan 5, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, January 28, 2016 at 9 a.m. ET to discuss fourth quarter and full-year 2015 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgen...
Jan 11, 2016 2016 Guidance for Net Product Sales and Diluted EPS Preliminary 2015 Unaudited Financial Results Including Net Product Sales and Diluted EPS Affirming 2020 Net Product Sales and Adjusted Diluted EPS Financial Targets SUMMIT, ...
Jan 11, 2016 - Bob Hugin to continue to lead strategic direction of Company in the role of Executive Chairman - Mark Alles to be promoted to Chief Executive Officer - Jacqualyn Fouse, PhD, to be promoted to President & Chief Operating Officer SUMMIT, N.J.--(BUSINE...
Jan 22, 2016 10 abstracts including AG as an investigational foundation in first-line metastatic pancreatic cancer research being presented during the meeting SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that 10 studies highlighting combinations that include ...
Jan 22, 2016 Initiative Urges Public to Harness Their Online Power to Support the Community in Their Efforts to Generate Awareness SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the launch of Be Counted!, an educational initiative that unites advocates, experts...
Jan 22, 2016 Multiple analyses examined ABRAXANE (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine followed by 5-FU-based regimens SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that results from multiple analyses pr...
Jan 28, 2016 Data from at Least 18 Phase III Trials Expected from Mid-2016 Through Mid-2018 2016 Guidance for Total Net Product Sales, REVLIMID® Net Sales and Diluted EPS SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported operating...
Feb 1, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences, where Celgene management will provide an overview of the Company. The conferences will be webcast live and the webcast will be available in the Investor Relations section of the Company's ...
Feb 11, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the election of Mark Alles and Jacqualyn Fouse PhD to its Board of Directors. Mr. Alles has been with Celgene since 2004, most recently serving as President and Chief Operating Officer (COO). Effective March 1, 2016,...
Feb 18, 2016 Reductions in brain lesions at week 24 were maintained while relapses were further reduced at week 72 with continuous ozanimod treatment No new safety or tolerability issues were identified during this blinded extension SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corpora...
Feb 27, 2016 Analyses demonstrated that QoL measures were maintained or improved in patients with advanced squamous non-small cell lung cancer undergoing initial treatment with ABRAXANE and carboplatin SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that two interim ...
Feb 29, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and the webcast will be available in the Investor Relations section of the Company's ...
Mar 4, 2016 Pooled ESTEEM 1 and 2 182-week data will report on long-term exposure of OTEZLA in patients with moderate to severe plaque psoriasis One-year data from LIBERATE™ trial assesses efficacy of OTEZLA in patients continuing on OTEZLA and those who switched from etanercept SU...
Mar 7, 2016 Pooled 3.5-year (182-week) data from ESTEEM 1 and 2 trials of OTEZLA for patients with moderate to severe plaque psoriasis showed no increases in the severity or frequency of adverse events and no new safety signals The rates of major cardiac events, malignancies, depression and suicidali...
Mar 7, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG, CELGZ) today announced it has received a Paragraph IV Notice Letter advising that Actavis LLC submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking authorization from the FDA to manufa...
Mar 18, 2016 In patients with moderate to severe ulcerative colitis, histologic improvement was greater with ozanimod 1 mg versus placebo at weeks 8 and 32 A greater proportion of patients achieved histologic remission at week 32 with ozanimod 1 mg versus placebo Data shared in oral pr...
Apr 1, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 28, 2016 at 9 a.m. ET to discuss first quarter 2016 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Apr 27, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and the webcast will be available in the Investor Relations section of the Company's ...
Apr 28, 2016 - Strong Operating Momentum Drives Q1 Results - 2016 Guidance: Raising Lower-End of Ranges for Net Product Sales and Adjusted Diluted EPS - 2017 Financial Targets Updated; 2020 Financial Targets On-Track SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corpora...
May 17, 2016 - New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment - -...
May 18, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced more than 65 presentations reporting on investigational studies in blood and solid tumor cancers will be presented during the 52ndAmerican Society of Clinical Oncology meeting in Chicago, Ill. from June 3-7, 2016. ...
May 20, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and the webcast will be available in the Investor Relations section of the Company's ...
Jun 3, 2016 Analysis of three phase III studies presented at ASCO annual meeting shows a 26% reduction in the risk of death, representing an estimated 2.5-year increase in median survival versus placebo or no maintenance SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced d...
Jun 4, 2016 Multiple presentations evaluate the treatment sequence with ABRAXANE plus gemcitabine in the first line setting and as a foundation for investigational combinations SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored...
Jun 7, 2016 Analysis shows gaps in treatment initiation and access between Caucasians and African Americans following multiple myeloma diagnosis SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the presentation of a study comparing treatment patterns, healthcare costs an...
Jun 9, 2016 Continuing its commitment to meeting unmet needs in rare blood cancers, data presented at congress will help inform the future of patient care in hematology SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on...
Jun 10, 2016 - Longer term data with investigational drug luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden, and improved patient reported quality of life measures in patients with beta-thalassemia - - Acceleron to host conference call and live webcast today...
Jun 10, 2016 - Preliminary results show that treatment with investigational drug luspatercept results in clinically meaningful increases in hemoglobin and durable transfusion independence in patients with lower risk myelodysplastic syndromes - - Acceleron to host conference call and live webcast today at 8:00 ...
Jun 15, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Company's common stock. This open-ended program is effective immediately. Purchases m...
Jun 22, 2016 Pioneering Public-Private Cancer Initiative with Unified Leadership Committed to Changing the Course of Cancer Care NEW YORK--(BUSINESS WIRE)-- Today, The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University ...
Jul 1, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, July 28, 2016 at 9 a.m. ET to discuss second quarter 2016 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Jul 15, 2016 Approved indication for REVLIMID® (lenalidomide) offers a new option for European patients with relapsed/refractory MCL, one of the poorest prognoses among all lymphomas Approval gives Celgene its first opportunity to support unmet needs of lymphoma patients across the European Union ...
Jul 25, 2016 SUMMIT, N.J. & LYON, France--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and the Lymphoma Study Association (LYSA) today announced that the Lymphoma Academic Research Organisation (LYSARC) reported initial data from a phase III, randomized, double-blind, international clinical study (REMARC). This ...
Jul 28, 2016 - Net Product Sales $2.74B in Q2:16: Increased 22% Y/Y - REVLIMID® Net Product Sales $1.7B in Q2:16; Increased 18% Y/Y - 2016 Guidance Updated: REVLIMID® and Total Net Product Sales; EPS SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corpo...
Aug 17, 2016 New Campaign Aims to Inspire People With Psoriasis to Show More of Their True Selves SUMMIT, N.J.--(BUSINESS WIRE)-- Twelve-time Olympic medalist, best-selling author, host of a cable sports TV show, and mom Dara Torres dives into a very important conversation this summer as she tea...
Aug 29, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences and at an R&D deep dive in September where Celgene management will provide an overview of the Company. The conferences and R&D deep dive will be webcast live and the webcasts will be available i...
Sep 12, 2016 Data show endoscopic improvement and clinical response and remission at week 12 Safety and tolerability consistent with previous studies Results expected to be presented at upcoming medical meetings SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation ...
Sep 13, 2016 Celgene Unites With National Psoriasis Foundation to Elevate Awareness of Psoriatic Arthritis (PsA) and Rally Support for Patient Community SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and the National Psoriasis Foundation (NPF) have united to mark Wednesday, S...
Sep 16, 2016 Ozanimod demonstrated continued efficacy over 96 weeks on MRI and clinical measures of multiple sclerosis disease activity No new safety or tolerability issues were identified during the ongoing blinded extension BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene Interna...
Sep 28, 2016 Pooled 3-year data analyses from ESTEEM 1 and 2 and PALACE 1-3 trials showed no increase in incidence of adverse events, no new safety signals and improved tolerability with exposure to apremilast up to 156 weeks1 The rates of major adverse cardiovascular events, malignancies and serious infection...
Oct 3, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, October 27, 2016 at 9 a.m. ET to discuss third quarter 2016 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Oct 4, 2016 Celgene to hold an analyst call on October 18, 2016 at 9 a.m. ET SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the data from a randomized, double-blind, multicenter, exploratory phase Ib study evaluating the effects of oral GED-0301 (mongersen) on bot...
Oct 7, 2016 Multiple presentations evaluate ABRAXANE alone or in combination with novel agents and novel regimens to treat mPAC, NSCLC, and MBC SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced results from multiple sponsored and independent studies will be presented duri...
Oct 12, 2016 Companion diagnostic technology to be utilized with enasidenib (AG-221/CC-90007) and AG-120 development programs for relapsed/refractory acute myeloid leukemia (AML) Approximately 20% of AML patients have an IDH mutation SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ...
Oct 13, 2016 Exploratory phase 1b study interim data assessing the effects of oral GED-0301 (mongersen) on both endoscopic and clinical outcomes at 12 weeks in patients with active Crohn's disease TOUCHSTONE extension data assessing safety and efficacy of long term treatment with ozanimod, an oral S1P1 and 5 r...
Oct 16, 2016 Clinical improvement observed early, with highest clinical response and remission rates in the 12-week treatment group Endoscopic improvement seen across all treatment groups at 12 weeks Safety and tolerability were consistent with previous studies VIENNA--(BU...
Oct 17, 2016 Open-label extension of TOUCHSTONE study of ozanimod showed continued symptom improvement through week 44 of the extension Safety and tolerability were consistent with previous studies of ozanimod VIENNA--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly ow...
Oct 18, 2016 Observational study to examine the burden of chronic anemia in myelodysplastic syndromes and beta-thalassemia SUMMIT, N.J. & SEATTLE--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Sage Bionetworks today announced a collaboration to develop an iPhone application utilizing the Apple...
Oct 24, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences in November where Celgene management will provide an overview of the Company. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the ...
Oct 27, 2016 - Net Product Sales $2.97B in Q3:16; Increased 28% Y/Y - 2016 Guidance and 2017 Targets Updated - Over 150 Abstracts Expected at Medical Congresses in Q4 - FDA Grants Priority Review for REVLIMID® as Maintenance Treatment Post-Autologous Stem-Cell Transplant in...
Nov 14, 2016 ACTIVE trial in biologic-naïve patients met its primary endpoint, demonstrating significant improvement in ACR20 response rate at week 16 with OTEZLA versus placebo Improvements in ACR20 and other measures of disease seen as early as week 2 ACR20 response rate increas...
Nov 21, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to webcast an analyst and investor event being held at the American Society of Hematology (ASH) meeting in San Diego on December 4. The webcast will begin at 11pm ET and will be available in the Investor Relations section of the Company's ...
Nov 22, 2016 Presentations will focus on a wide range of disease areas including multiple myeloma, lymphoma, leukemia, myelodysplastic syndromes and beta-thalassemia SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that data from nearly 350 abstracts, including m...
Dec 3, 2016 Project will create the largest dataset of molecular profiling for patients with multiple myeloma leading to tests that could improve diagnosis, prognosis and new treatments SAN DIEGO--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG), Dana-Farber Cancer Institute and the Universi...
Dec 5, 2016 Patients with MDS, CMML or AML who were relapsed or refractory to prior HMA therapies and who received CC-486 had a 38% overall response rate SUMMIT, N.J.--(BUSINESS WIRE)-- Abstract #905 -- Celgene Corporation (NASDAQ:CELG), today announced results from an analysis of three phase I...
Dec 6, 2016 Interim study findings further support safety, efficacy and tolerability in squamous and elderly patients with advanced NSCLC, consistent with results previously seen in the pivotal Phase III trial BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced inter...
Dec 6, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG), today announced results from two studies (Abstracts #1143, LBA-1) evaluating the investigational use of REVLIMID® (lenalidomide) maintenance therapy in patients with multiple myeloma. These studies were presented at the 58th American ...
Dec 7, 2016 Phase II tnAcity Trial found a significantly longer Progression Free Survival with ABRAXANE + carboplatin compared to ABRAXANE + gemcitabine or carboplatin + gemcitabine regimens SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the results of it...
Dec 20, 2016 The first oral treatment in 25 years for patients in Japan with these diseases SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that OTEZLA® (apremilast), Celgene's oral selective inhibitor of phosphodiesterase 4 (PDE4), has been granted full ma...
Dec 20, 2016 -- Early results recently announced with JCAR017 in non-Hodgkin lymphoma and pediatric acute lymphoblastic leukemia -- Pivotal DLBCL trial expected to begin in 2017 SEATTLE & SUMMIT, N.J.--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO) and Celgene Corporation (NASDA...
Dec 22, 2016 First-in-class oral treatment for psoriatic arthritis made available via the National Health Service (NHS) STOCKLEY PARK, England--(BUSINESS WIRE)-- Celgene announced today that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) ...
Jan 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- During the 35th Annual J.P. Morgan Healthcare Conference on January 9, 2017 at 10:30 a.m. ET, Celgene Corporation (NASDAQ:CELG) will present a business update on the Company in addition to unaudited 2016 financial results and an updated financial outlook. The presentation and ...
Jan 4, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, January 26, 2017 at 9 a.m. ET to discuss fourth quarter and full-year 2016 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgen...
Jan 9, 2017 Preliminary 2016 Unaudited Financial Results Including Net Product Sales and Diluted EPS Raising 2017 Guidance for Total Revenue and Diluted EPS Reaffirming 2020 Total Revenue and Adjusted Diluted EPS Financial Targets SUMMIT...
PDF
Add to Briefcase
Jan 26, 2017 Expands pipeline of potential next-generation medicines for the treatment of patients with autoimmune disorders SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Delinia, Inc. ("Delinia"), a privately held biotechnology company developing novel therape...
Jan 26, 2017 Net Product Sales $2.98B in Q4:16; Increased 17% Y/Y Net Product Sales $11.18B in 2016; Increased 22% Y/Y 2017 Guidance for Net Product Sales and Diluted EPS SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported opera...
PDF
Add to Briefcase
Jan 27, 2017 REVLIMID® is the first and only medicine granted positive CHMP opinion for post-Autologous Stem Cell Transplantation (ASCT) maintenance therapy in MM The new indication expands the availability of REVLIMID® across the disease continuum of MM ...
Feb 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at an upcoming investor conference where Celgene management will provide an overview of the Company. The conference will be webcast live and will be available in the Investor Relations section of the Company's website at www.celgen...
Feb 17, 2017 Study met its primary endpoint in reducing annualized relapse rate (ARR) and measured secondary endpoints, compared to interferon (IFN) β-1a (Avonex®) Safety and tolerability consistent with phase II studies Confirmatory phase III RADIANCE trial data expected in Q2 of 201...
Feb 22, 2017 REVLIMID is the first and only treatment approved for maintenance following auto-HSCT Updated data from two large, randomized, controlled studies demonstrated median progression-free survival (PFS) advantages of 3.8 and 1.9 years, respectively, in favor of patients receiving REVLIMID comp...
Feb 23, 2017 - Jacqualyn Fouse, Ph.D., to retire from Celgene effective June 30, 2017 and will not stand for reelection to the Celgene Board of Directors - Scott Smith to be promoted to President and Chief Operating Officer, effective April 1, 2017 - Terrie Curran to be promoted to President, G...
Feb 24, 2017 Oral REVLIMID® is the first and only medicine licensed in Europe for use as post-autologous stem cell transplantation maintenance therapy in multiple myeloma The new indication expands the availability of REVLIMID® across the disease continuum of multiple myeloma ...
Feb 27, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.cel...
Mar 1, 2017 PDUFA date set for Aug. 30, 2017 SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene's New Drug Application (NDA) for enasidenib ...
Mar 3, 2017 UNVEIL evaluated the efficacy and safety of oral OTEZLA at 16 weeks in patients with moderate plaque psoriasis who were naïve to systemic and biologic therapy SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that findings from ongoing clinical t...
Mar 5, 2017 Data from UNVEIL, the first trial of patients with moderate plaque psoriasis (BSA 5-10 percent) who were naïve to systemic and biologic therapy, presented at American Academy of Dermatology Congress OTEZLA demonstrated significant improvements versus placebo for the primary and key secondary ...
Apr 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 27, 2017 at 9 a.m. ET to discuss first quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Apr 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) has received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc. submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking authorization from the FDA to manufacture an...
Apr 27, 2017 - Net Product Sales of $2.95B in Q1:17; Increased 18% Y/Y - REVLIMID® Net Product Sales of $1.9B in Q1:17; Increased 20% Y/Y - Raising 2017 EPS Guidance - Positive phase II STEPSTONE data with ozanimod in Crohn's disease; Phase III trial initiation pla...
May 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.c...
May 6, 2017 - Preliminary results show that treatment with investigational drug luspatercept achieves meaningful erythroid response rates and transfusion independence in first-line, lower-risk myelodysplastic syndromes patients - - Celgene and Acceleron plan to initiate a Phase 3 trial in first-line,...
May 17, 2017 Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative research SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that data from a broad range of company-sponsored and investigator-initiated studies ...
May 22, 2017 Study met the primary endpoint of annualized relapse rate (ARR) and key secondary MRI endpoints of T2 and GdE lesions, compared to interferon (IFN) β-1a (Avonex®); a very low rate of disability progression observed across the three treatment groups in the pooled analysis; disability endpoint not met ...
Jun 1, 2017 - Companies expect to report top-line results from the Phase 3 studies in mid-2018 - SUMMIT, N.J. & CAMBRIDGE, Ma.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that they have completed target enrollment in the MEDALIS...
Jun 5, 2017 - 100% of the 15 evaluable patients in active dose cohorts (doses above 50 x 106) achieved an objective response; overall response rate (ORR) across all cohorts (n=18) is 89% - - 73% of evaluable patients in active dose cohorts achieved a very good partial response (VGPR) or better; 27% complete r...
Jun 6, 2017 40.3% Overall Response Rate (ORR) with Median Duration of Response of 5.8 Months and 19.3% Complete Response (CR) Rate with Median Duration of Response of 8.8 Months in Patients With a CR Overall Safety Profile was Consistent with Previously Reported Data Simultaneous Online Public...
Jun 14, 2017 Data showed positive trend in multiple disease measures versus placebo Results presented at the Annual European Congress of Rheumatology (EULAR) 2017 BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporat...
Jun 17, 2017 Interim data from the study evaluating the investigational chemotherapy-free R2 combination regimen, presented at ASCO and expanded data presented at ICML Results showed clinical activity across indolent non-Hodgkin lymphomas, marginal zone and follicular histologies, as well as responses...
Jun 19, 2017 Presentations highlight innovative research in multiple disease areas including multiple myeloma, lymphoma, leukemia, myelodysplastic syndromes and beta-thalassemia BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that data from a broad range ...
Jun 22, 2017 Powerful, New Portraits Aim to Inspire People With Plaque Psoriasis or Psoriatic Arthritis to Show More of Their True Selves SUMMIT, N.J.--(BUSINESS WIRE)-- Award-winning portrait photographer Martin Schoeller along with 12-time Olympic medalist and New York Times best-selling author Dara To...
Jul 5, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, July 27, 2017 at 9 a.m. ET to discuss second quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Jul 5, 2017 Celgene accelerates its immuno-oncology strategy in solid tumors with acquisition of worldwide rights, rest of world outside Asia, to BeiGene's PD-1 inhibitor BGB-A317; Pivotal BGB-A317 solid tumor studies planned for 2018 Collaboration maximizes potential for best-in-class PD-1-based ...
Jul 25, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that it has reached a civil settlement with Relator Brown, the Department of Justice, 28 States, the District of Columbia, and the City of Chicago to resolve the previously disclosed False Claims Act litigation pending in the United...
Jul 27, 2017 - Strong Q2 performance; Updated 2017 EPS guidance - Positive ozanimod phase III data in relapsing multiple sclerosis (RMS) advances neuroscience franchise opportunities - Completed enrollment in five phase III trials during Q2, with data expected in 2018; Multiple phase III data r...
Jul 28, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at an upcoming investor conference where Celgene management will provide an overview of the Company. The conference will be webcast live and will be available in the Investor Relations section of the Company's website at www.celgen...
Aug 1, 2017 IDHIFA is the first and only oral, targeted inhibitor of IDH21 FDA approval of IDHIFA was based on results from the phase I/II AG-221 AML-001 study including safety, rate and duration of complete response (CR) or CR with partial hematologic recovery (CRh) and rate of conversion to transfusion inde...
Aug 24, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at four upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.ce...
Sep 7, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION™ program. The trials are testing IMFINZI™ (durvalumab), an an...
Sep 8, 2017 Multiple presentations evaluate the investigational uses of ABRAXANE alone or as combination therapy to treat non-small cell lung cancer and as combination therapy for locally advanced pancreatic cancer BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced ...
Oct 2, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Oct 16, 2017 In the STEPSTONE open-label study, ozanimod demonstrated meaningful clinical and endoscopic improvements in patients with moderately to severely active Crohn's disease at week 12 In the TOUCHSTONE open-label extension study, ozanimod continued to demonstrate clinically meaningful results in modera...
Oct 19, 2017 Ozanimod highlighted in two oral presentations detailing results from phase III SUNBEAM™ and RADIANCE™ trials in RMS Additional clinical and non-clinical poster presentations will further characterize the profile of ozanimod SUMMIT, N.J.--(BUSINESS WIRE)-...
Oct 19, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that the GED-0301 (mongersen) phase III REVOLVE trial (CD-002) in Crohn's disease (CD) and the extension trial (SUSTAIN, CD-004) will discontinue. Celgene has decided to stop the trials following an October recommendation of the ...
Oct 26, 2017 - Updating 2017 guidance and financial targets for 2020 - Data from multiple next generation growth drivers being presented at 14 major global medical meetings in Q4 including ECTRIMS, UEGW and ASH SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported net...
Oct 27, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www....
Oct 27, 2017 Ozanimod demonstrated superiority versus interferon beta-1a (Avonex®) in reducing annualized relapse rates and MRI brain lesions Incidence of adverse events and serious adverse events similar to Avonex Safety and tolerability profile consistent with prior phase II studies ...
Oct 28, 2017 Ozanimod demonstrated superiority versus interferon beta-1a (Avonex®) in reducing annualized relapse rates and MRI brain lesions at two years Incidence of adverse events and serious adverse events similar to Avonex Safety and tolerability profile consistent with prior phase II...
Oct 31, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity d...
Nov 1, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $3,000 million. Of these notes, $750 million will mature in 2023 and will bear interest at an annual rate of 2.750 percen...
Nov 16, 2017 Designations based on preliminary clinical data from ongoing phase I study of bb2121 in heavily pre-treated multiple myeloma SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antig...
Nov 21, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) plans to webcast an analyst and investor event being held at the American Society of Hematology (ASH) meeting in Atlanta on December 10. The webcast will begin at 8pm ET and will be available in the Investor Relations section of the Company's ...
Nov 21, 2017 Presentations will focus on a wide range of disease areas including multiple myeloma, lymphoma, acute myeloid leukemia, myelodysplastic syndromes and beta-thalassemia and novel technologies such as CAR-T cell therapy SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) ...
Dec 5, 2017 Grant Program Will Help Fund Cancer Care Capability, Delivery and Access Programs SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the launch of Celgene Cancer Care Links, a new grant program designed to support cancer healthcare capacity building in...
Dec 7, 2017 -- Phase III Secondary Endpoint Results Demonstrate A Significantly Higher Disease-free Survival Rate following ABRAXANE as Investigational Therapy in Neoadjuvant Breast Cancer -- NEU-ISENBURG, Germany & SUMMIT, N.J.--(BUSINESS WIRE)-- The German Breast Group (GBG) and Celgene Corporation (N...
Dec 10, 2017 Overall response rate (ORR) of 94% in patients in active dose cohorts (doses above 50 x 106 CAR + T-cells) Complete Response (CR) rate of 56% observed in patients in active dose cohorts Median progression free survival (PFS) not reached with median follow up of 40 weeks in...
Dec 11, 2017 —74% (14/19) ORR and 68% (13/19) CR rate at 3 months and 50% (7/14) CR at 6 months in core group at dose level 2— —Across doses, 80% (16/20) of core group patients in CR at month 3 remain in response at month 6; 92% (11/12) of core group patients in response at 6 months remain in...
Page:
1
Add to Briefcase = add release to Briefcase